{
    "organizations": [],
    "uuid": "2d9a8a21be1ce671dbea2e15c587978771ea3079",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-athenex-announces-encouraging-earl/brief-athenex-announces-encouraging-early-clinical-efficacy-and-safety-data-of-oraxol-idUSASB0C1NU",
    "ord_in_thread": 0,
    "title": "BRIEF-Athenex Announces Encouraging Early Clinical Efficacy And Safety Data Of Oraxol",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 22 (Reuters) - Athenex Inc:\n* ATHENEX ANNOUNCES ENCOURAGING EARLY CLINICAL EFFICACY AND SAFETY DATA OF ORAXOL IN CLINICAL TRIAL FOR THE TREATMENT OF BREAST CANCER\n* ATHENEX - ‍AMONG FIRST 12 EVALUABLE PATIENTS, 50% HAD PARTIAL RESPONSE, 50% HAD STABLE DISEASE IN TRIAL OF ORAXOL FOR TREATMENT OF BREAST CANCER​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-22T20:17:00.000+02:00",
    "crawled": "2018-01-23T17:59:58.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "athenex",
        "inc",
        "athenex",
        "announces",
        "encouraging",
        "early",
        "clinical",
        "efficacy",
        "safety",
        "data",
        "oraxol",
        "clinical",
        "trial",
        "treatment",
        "breast",
        "cancer",
        "athenex",
        "first",
        "evaluable",
        "patient",
        "partial",
        "response",
        "stable",
        "disease",
        "trial",
        "oraxol",
        "treatment",
        "breast",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}